Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
viernes, octubre 23
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Rhythm Pharmaceuticals Inc
RYTM
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$90.90
2.28
2.57%
Últ. Act.: Oct 22, 4:00 PM
$90.90
2.28
2.57%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Ganancias:
Beneficios de Q3 2026 dentro de 11 días de ahora en mar nov 3rd, antes de la apertura del mercado
Rhythm Pharmaceuticals Financials
Rhythm Pharmaceuticals (RYTM) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Rhythm Pharmaceuticals Q2 EPS $(0.73) Beats $(0.82) Estimate, Sales $71.255M Beat $67.277M Estimate
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.82) by 10.98 percent. This is a 2.67 percent increase over losses of $(0.75) per share
Benzinga Newsdesk
Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported better-than-expected earnings, with strong demand for IMCIVREE and potential launches in Europe and Japan.
Avi Kapoor
Earnings Scheduled For May 5, 2026
Benzinga Insights
PRO
Rhythm Pharmaceuticals Anticipates Approximately $385M-$415M In Non-GAAP Operating Expenses In Fiscal 2026
Benzinga Newsdesk
PRO
Rhythm Pharmaceuticals Q1 EPS $(0.83) Beats $(0.84) Estimate, Sales $60.112M Beat $55.776M Estimate
Benzinga Newsdesk
Stock Market Today: Dow, S&P 500 Futures Tick Up As Oil Prices Rise, US Allies Reject Trump's Hormuz Call— Uber, Lululemon, Cisco In Focus (UPDATED)
(Editor’s note: The future prices of benchmark tracking ETFs, the lede, and the headline were updated in the story.) Dow Jones and S&P 500 futures pared earlier losses to trade slightly up on Tuesday, while Nasdaq futures were trading lower following Monday’s gains. Futures of the major benchmark indices were mixed.
Rishabh Mishra
